MGNX MacroGenics, Inc.
Price Chart
Executive Summary
MacroGenics is selling its GMP drug substance manufacturing operations to Bora Pharmaceuticals for a $122.5 million upfront payment. The deal transfers the Rockville, MD facility (11,000L capacity), Frederick warehouse, and ~140 employees to Bora, while MacroGenics retains a supply arrangement for its pipeline needs. This non-dilutive capital infusion supports the company's pipeline advancement but reflects a strategic pivot away from internal manufacturing.
Key Financial Metrics
Actionable Insight
The $122.5M upfront provides near-term cash runway extension without dilution, but the sale of manufacturing capabilities signals a shift to a more asset-light model. Monitor Q3 2026 closing and any pipeline updates (e.g., lorigerlimab data) that could drive re-rating. Historical performance on MGNX shows poor follow-through on bullish calls — be cautious on upside.
Key Facts
- Upfront payment of $122.5 million from Bora Pharmaceuticals upon closing.
- Transfer of Rockville, MD manufacturing site (11,000L capacity) and Frederick, MD warehouse.
- Approximately 140 MacroGenics employees expected to be hired by Bora.
- MacroGenics will have a supply arrangement with Bora for process development and drug substance production.
- Transaction expected to close in Q3 2026.
- Moelis & Company and Sidley Austin advised MacroGenics; Jones Day advised Bora.
Financial Impact
$122.5 million upfront payment, non-dilutive capital for pipeline funding.
Risk Factors
- Closing conditions may delay or prevent transaction completion.
- Loss of internal manufacturing control could increase dependency on Bora for supply.
- Pipeline setbacks (e.g., clinical trial failures) could erode the value of the capital infusion.
- Historical T+20 performance on MGNX bullish calls is poor (25% win rate, avg -0.51% T+20).
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292410 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
Institutional Cluster
| $4.01 awaiting T+5 | awaiting T+5 | — | $3.96 (−1.25%) |
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $3.87 awaiting T+5 | awaiting T+5 | — | $3.96 (+2.33%) |
|
May 13, 2026
4w ago
|
8-K
| $4.16 $4.24 | ▲ +1.92% | ▲ +2.64% | $3.96 (−4.81%) |
|
May 12, 2026
4w ago
|
8-K
| $3.52 $4.35 | ▲ +23.58% | ▲ +23.50% | $3.96 (+12.50%) |
|
May 11, 2026
4w ago
|
Press Release
| $3.52 $4.35 | ▲ +23.58% | ▲ +23.50% | $3.96 (+12.50%) |
|
Apr 8, 2026
9w ago
|
8-K
| $3.44 $3.41 | ▼ −0.87% | ▼ −4.06% | $3.96 (+15.12%) |
|
Apr 8, 2026
9w ago
|
Press Release
| $3.44 $3.41 | ▼ −0.87% | ▼ −4.06% | $3.96 (+15.12%) |
|
Apr 8, 2026
9w ago
|
DEFA14A
| $3.44 $3.41 | ▼ −0.87% | ▼ −4.06% | $3.96 (+15.12%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $1.94 $2.36 | ▲ +21.65% | ▲ +22.86% | $3.96 (+104.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access